AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

TORONTO, Nov. 20, 2024 /PRNewswire/ — AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company’s patented AmacaGel™ platform, demonstrating sustained anesthetic release out to 14 days. AMT-143 is…